Advertisement
Advertisement
TRDA
Entrada Therapeutics, Inc. Common Stock
10.62
USDSponsored
+0.54
+5.41%
Feb 06, 15:59 UTC -5
Closed
After-Market
10.61
-0.01
-0.05%
TRDA Earnings Reports
Positive Surprise Ratio
TRDA beat 8 of 17 last estimates.
47%
Next Report
Date of Next Report
Feb 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
$14.16M
/-$1.18
Implied change from Q3 25 (Revenue/ EPS)
+777.55%
/+11.32%
Implied change from Q4 24 (Revenue/ EPS)
-62.13%
/-4033.33%
Entrada Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 06, 2025, TRDA reported earnings of -1.06 USD per share (EPS) for Q3 25, missing the estimate of -0.95 USD, resulting in a -10.55% surprise. Revenue reached 1.61 million, compared to an expected 13.98 million, with a -88.45% difference. The market reacted with a +0.14% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -1.18 USD, with revenue projected to reach 14.16 million USD, implying an increase of 11.32% EPS, and increase of 777.55% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Entrada Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Entrada Therapeutics, Inc. Common Stock reported EPS of -$1.06, missing estimates by -10.55%, and revenue of $1.61M, -88.45% below expectations.
How did the market react to Entrada Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 0.14%, changed from $6.94 before the earnings release to $6.95 the day after.
When is Entrada Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 25, 2026.
What are the forecasts for Entrada Therapeutics, Inc. Common Stock's next earnings report?
Based on 7
analysts, Entrada Therapeutics, Inc. Common Stock is expected to report EPS of -$1.18 and revenue of $14.16M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement